SCYNEXIS, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by SCYNEXIS, Inc. (SCYX) on September 21, 2026, reporting events occurring on September 18, 2026. The filing discloses the appointment of a new member to the Board of Directors and associated compensatory arrangements.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial figures disclosed relate to director compensation:
- Annual Cash Retainer: $45,000
- Committee Retainer: $5,000 (Nominating and Corporate Governance Committee)
- Initial Stock Option Grant: 5,750 shares at an exercise price of $4.46 per share.
- Initial Restricted Stock Unit (RSU) Grant: 5,750 shares.
Material Changes
The primary material change reported is the appointment of Steven K. Burke, M.D., as a member of the Board of Directors, effective September 18, 2026. Dr. Burke was also appointed to the Nominating and Corporate Governance Committee. His term will last until the 2027 Annual Meeting of Stockholders.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of specific risks or contingencies beyond the standard indemnification agreement entered into with the new director. The press release regarding this appointment is included as an exhibit but is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the vesting schedule details for the initial stock options (one-third at one year, remainder monthly over 24 months) and RSUs (one-third annually).
- Confirm the closing stock price of $4.46 on September 18, 2026, which set the exercise price for the initial option grant.
- Review the Company's Non-Employee Director Compensation Policy to understand the structure of future annual equity grants (2,875 options and 2,875 RSUs).
- Check for any potential conflicts of interest or transactions involving Dr. Burke under Item 404(a) of Regulation S-K, though the filing states none are currently known.